Title |
Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML)
|
---|---|
Published in |
Journal of Cancer Research and Clinical Oncology, April 2014
|
DOI | 10.1007/s00432-014-1666-7 |
Pubmed ID | |
Authors |
Ulf Schnetzke, Peter Fix, Baerbel Spies-Weisshart, Karin Schrenk, Anita Glaser, Hans-Joerg Fricke, Paul La Rosée, Andreas Hochhaus, Sebastian Scholl |
Abstract |
Approximately, 70 % of adult patients with de novo acute myeloid leukemia (AML) achieve a complete remission (CR) while 10-20 % of AML are refractory to induction chemotherapy. Furthermore, a significant proportion of AML patients in CR will relapse during or after consolidation treatment. There is no evidence for a standard salvage regimen and most centers use a combination of an anthracycline and cytarabine (AraC). The aim of this study was to investigate the impact of two age-adjusted regimens containing AraC and cyclophosphamide applied for the treatment of relapsed or refractory AML. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 4% |
United States | 1 | 4% |
Unknown | 22 | 92% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 5 | 21% |
Researcher | 5 | 21% |
Other | 4 | 17% |
Student > Master | 4 | 17% |
Student > Ph. D. Student | 1 | 4% |
Other | 2 | 8% |
Unknown | 3 | 13% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 11 | 46% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 13% |
Agricultural and Biological Sciences | 3 | 13% |
Biochemistry, Genetics and Molecular Biology | 2 | 8% |
Engineering | 1 | 4% |
Other | 0 | 0% |
Unknown | 4 | 17% |